Back

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

Sapkal, G. N.; Yadav, P.; Ella, R.; Deshpande, G.; Sahay, R.; Gupta, N.; Mohan, V. K.; Abraham, P.; Panda, S.; Bhargava, B.

2021-01-26 molecular biology
10.1101/2021.01.26.426986 bioRxiv
Show abstract

We performed the plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.